Protecting trade secrets, patents, copyrights, and trademarks /

Por Dorr, Robert C., Munch, Christopher H.
Publicado em 1990

Inhibition of protein synthesis by imexon reduces HIF-1α expression in normoxic and hypoxic pancreatic cancer cells

Por Samulitis, Betty K., Landowski, Terry H., Dorr, Robert T.
Publicado em 2008

The Diaryl Oxazole PC-046 is a Tubulin-Binding Agent with Experimental Anti-Tumor Efficacy in Hematologic Cancers

Por Landowski, Terry H., Samulitis, Betty K., Dorr, Robert T.
Publicado em 2013

Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines

Por Scott, Julie, Dorr, Robert T., Samulitis, Betty, Landowski, Terry H.
Publicado em 2007

Proteasomal inhibition stabilizes topoisomerase IIα protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide)

Por Congdon, Lauren M., Pourpak, Alan, Escalante, Aluvia M., Dorr, Robert T., Landowski, Terry H.
Publicado em 2007

Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase

Por Roman, Nicholas O., Samulitis, Betty K., Wisner, Lee, Landowski, Terry H., Dorr, Robert T.
Publicado em 2010

Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423

Por Dorr, Robert T., Wisner, Lee, Samulitis, Betty K., Landowski, Terry H., Remers, William A.
Publicado em 2011

Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium

Por Guntle, Gerald P, Jagadish, Bhumasamudram, Mash, Eugene A, Powis, Garth, Dorr, Robert T, Raghunand, Natarajan
Publicado em 2012

Synthesis, Characterization and Anti-Melanoma Activity of Tetra-O-substituted Analogs of Nordihydroguaiaretic Acid

Por Meyers, Ross O., Lambert, Joshua D., Hajicek, Nicole, Pourpak, Alan, Kalaitzis, John A., Dorr, Robert T.
Publicado em 2009

Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer Cells

Por Sheveleva, Elena V., Landowski, Terry H., Samulitis, Betty K., Bartholomeusz, Geoffrey, Powis, Garth, Dorr, Robert T.
Publicado em 2012

Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo

Por Escalante, Aluvia M., McGrath, Ryan T., Karolak, Matthew R., Dorr, Robert T., Lynch, Ronald M., Landowski, Terry H.
Publicado em 2013

Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model()

Por Landowski, Terry H., Guntle, Gerald P., Zhao, Dezheng, Jagadish, Bhumasamudram, Mash, Eugene A., Dorr, Robert T., Raghunand, Natarajan
Publicado no Transl Oncol (2016)

α6 Integrin Cleavage: Sensitizing human prostate cancer to ionizing radiation

Por PAWAR, SANGITA C., DOUGHERTY, SHONA, PENNINGTON, MICHAEL E., DEMETRIOU, MANOLIS C., STEA, B. DINO, DORR, ROBERT T., CRESS, ANNE E.
Publicado em 2007

UA62784; a novel inhibitor of CENP-E kinesin-like protein

Por Henderson, Meredith C., Shaw, Yeng-Jeng Y., Wang, Hong, Han, Haiyong, Hurley, Laurence H., Flynn, Gary, Dorr, Robert T., Von Hoff, Daniel D.
Publicado em 2009

Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance

Por TOME, MARGARET E., FRYE, JENNIFER B., COYLE, DONNA L., JACOBSON, ELAINE L., SAMULITIS, BETTY K., DVORAK, KATERINA, DORR, ROBERT T., BRIEHL, MARGARET M.
Publicado em 2012

Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors

Por Samulitis, Betty K, Pond, Kelvin W, Pond, Erika, Cress, Anne E, Patel, Hitendra, Wisner, Lee, Patel, Charmi, Dorr, Robert T, Landowski, Terry H
Publicado no Cancer Biol Ther (2014)

The Antitumor Agent Imexon Activates Antioxidant Gene Expression: Evidence for an Oxidative Stress Response

Por Baker, Amanda F., Landowski, Terry, Dorr, Robert, Tate, Wendy R., Gard, Jaime M.C., Tavenner, Breonna E., Dragovich, Tomislov, Coon, Amy, Powis, Garth
Publicado em 2007

Characterization of Novel Diaryl Oxazole-Based Compounds as Potential Agents to Treat Pancreatic Cancer

Por Shaw, Arthur Y., Henderson, Meredith C., Flynn, Gary, Samulitis, Betty, Han, Haiyong, Stratton, Steve P., Chow, H.-H. Sherry, Hurley, Laurence H., Dorr, Robert T.
Publicado em 2009

Original Article A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer

Por Cohen, Steven J., Zalupski, Mark M., Modiano, Manuel R., Conkling, Paul, Patt, Yehuda Z., Davis, Peg, Dorr, Robert T., Boytim, Michelle L., Hersh, Evan M.
Publicado em 2009

Characterization of a membrane-active anti-tumor agent, UA8967

Por Dorr, Robert T., Samulitis, Betty K., Wisner, Lee, Han, Haiyong, Zhao, Yu, Beroza, Paul, Damodaran, Komath, Igarashi, Suzu, Landowski, Terry H., Von Hoff, Daniel D.
Publicado em 2012